QuatRx Pharmaceuticals Co., an Ann Arbor, Mich.-based drug company focused on endocrine, metabolic and cardiovascular disorders, has raised $44 million in Series E funding. The capital will be used to complete ongoing Phase 3 and Phase 2 clinical studies of QuatRx's two endocrine programs, and Phase 1 clinical studies with its lipid-lowering compound. Venrock led the round, and was joined by fellow new investors T. Rowe Price, Catella Healthcare and Hercules Technology Growth Capital. Return backers include Frazier Healthcare Ventures, TL Ventures, MPM Capital, InterWest Partners, Thomas Weisel Healthcare Ventures, Stockwell Capital, H&B Capital, BioMedical Ventures, Bio Fund Ventures and Twilight Venture Partners. Aquilo Partners served as placement agent.
QuatRx has now raised over $116 million in total VC funding since 2000, including a Series D round in 2005 that valued the company at around $106 million. It filed for an IPO last year, but later withdrew due to “unfavorable market conditions.” www.quatrx.com